Top 5 Articles of the Month: April 2026

To stay up to date with the latest dermatology news, sign up to receive our e-newsletters.

1. Reactivating the Follicle: PP405 Moves Toward Late-Stage Trials for Alopecia

In an interview with Dermatology Times, Christina Weng, MD, and Daniel Gil, PhD, discussed PP405, a novel topical therapy for alopecia that aims to regenerate hair by reactivating dormant hair follicle stem cells. Unlike existing treatments that mainly slow hair loss or improve hair thickness, PP405 targets the underlying biology of hair growth by stimulating inactive follicles to re-enter the growth phase. Early phase 2a data showed increased follicular unit activation and terminal hair growth with a favorable safety profile and no systemic absorption. With further trials planned, PP405 could represent a shift toward regenerative, mechanism-based treatment for hair loss in both men and women.

MORE ON ALOPECIA

2. Dermocosmetic Cream Shows Early Acne Improvement in Skin of Color

A small exploratory study in adults with acne vulgaris and darker skin phototypes (Fitzpatrick types IV-VI) found that a multitargeted dermocosmetic cream may improve both acne lesions and acne-induced hyperpigmentation, a common and often more distressing sequela in patients with skin of color. In a split-face design, the treated side showed earlier and greater reductions in total and inflammatory lesions, along with significant improvements in hyperpigmentation intensity over 57 days compared with an untreated control. Although the number of pigmentary lesions did not change, their severity decreased, and tolerability was favorable. These findings suggest that dermocosmetics may play a useful adjunctive role in managing both inflammation and pigmentary changes in this population, though larger studies are needed.

MORE ON ACNE

3. Oral TYK2 Inhibitors Challenge Biologics in Psoriasis

Advances presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting highlighted a major shift in psoriasis care, with next-generation tyrosine kinase 2 (TYK2) inhibitors such as envudeucitinib and zasocitinib demonstrating efficacy that approaches biologic therapies. Both agents achieved high rates of skin clearance, including meaningful reductions of 90% or greater in the Psoriasis Area and Severity Index (PASI) score (PASI 90) and complete clearance (PASI 100), along with rapid symptom improvement and favorable safety profiles. These findings suggest that oral therapies may soon offer biologic-level outcomes, expanding treatment options and improving shared decision-making for patients with moderate to severe psoriasis.

MORE FROM DERMATOLOGY TIMES NP/PA CONNECT

4. Insights From the Multinational RWEAL Study on CHE Etiology, Severity, and Real-World Management

A 12-month phase 3 program (SCALP 1 [NCT05910450] and SCALP 2 [NCT05914805]) evaluating clascoterone 5% topical solution in men with androgenetic alopecia showed sustained hair growth and a favorable long-term safety profile. Across more than 1400 participants, the topical androgen receptor inhibitor demonstrated continued increases in hair count with ongoing use and no meaningful systemic hormonal adverse effects, supporting its potential as a chronic therapy. Patients who remained on treatment experienced greater improvements in hair growth and satisfaction compared with those who discontinued, reinforcing the importance of continuous therapy. Regulatory submissions are planned, with the therapy positioned as a potential first-in-class topical option targeting the underlying biology of male pattern hair loss.

MORE DRUGS TO WATCH

5. Contextualizing the JAK Inhibitor Black Box Warning in Dermatology

At the 2026 AAD Annual Meeting, Diego Ruiz Dasilva, MD, and colleagues challenged common perceptions around the boxed warning for Janus kinase (JAK) inhibitors, emphasizing that much of the safety concern originates from studies in nondermatologic populations. They highlighted growing clinical and real-world evidence supporting broader use in atopic dermatitis while also pointing to a shifting treatment landscape in psoriasis as newer oral agents begin to approach biologic-level efficacy. The discussion underscored the need for balanced risk counseling, shared decision-making, and more thoughtful expectations around treatment timelines.

MORE FROM AAD